Opinion in Europe

Published within

« | ... | 1015 | 1016 | 1017 | 1018 | 1019 | 1020 | 1021 | 1022 | 1023 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

PLA Innovation of the Week: a dual-compartment juice container for enhanced shelf life

Published By Datamonitor
01 May 2012
Expert View
Expert View

Employers should be wary of setting a mandatory retirement age following UK Supreme Court ruling

A recent Supreme Court ruling found that an employer was justified in forcing the retirement of a senior employee because it was in the "public interest." This means that companies could potentially dismiss older workers to make way for younger staff. However, employers will be taking a significant risk in setting their own mandatory retirement age, and should investigate alternative approaches.

Published By Datamonitor
01 May 2012
Expert View
Expert View

Extra regulation should not ignore the fact that payday lenders meet a consumer need

There have been calls for limits to be imposed on the amount that payday lenders can charge their customers. However, with an increasing number of people needing short-term loans, these companies do have a role to play in the market. Authorities must avoid imposing excessive controls in this area so as not to create a situation where consumers instead borrow from unregulated, illegal loan sharks.

Published By Datamonitor
01 May 2012
CommentWire
CommentWire

The imminent rise of t-commerce

Among the plethora of statistics given to analysts by N Brown executives at its trading announcement was the staggering growth of its mobile traffic. It has risen to 14% from 4% of all e-commerce traffic, and the retailer now expects this to rise to 22% by the end of 2012. These mobile customers are not just browsing either, as N Brown is making sales of GBP1m a week from m-commerce.

Published By Datamonitor
02 May 2012
Expert View
Expert View

AAN 2012: BG-12 remains main focus of Biogen's extensive MS portfolio

Biogen used the platform of the 64th American Academy of Neurology Annual Meeting to provide updates on its extensive MS portfolio. Much time was devoted to its Phase III pipeline candidate BG-12, which looks set to be the next agent to enter the market, as well as the presentation of long-term safety data for Tysabri.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: Novartis presents new data in an attempt to boost confidence in long-term use of Gilenya

In keeping with American Academy of Neurology meetings of recent years, multiple sclerosis once again dominated proceedings at AAN 2012. Novartis used the platform to present new data from the extension FREEDOMS II trial to support the long-term use of Gilenya, and provided Phase II results for siponimod in relapse remitting multiple sclerosis.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: pooled data support future use of late-stage MS and epilepsy products

Teva, Eisai, and GlaxoSmithKline all used the opportunity of this year's American Academy of Neurology Annual Meeting to showcase pooled analysis of their late-stage pipeline candidates. While not groundbreaking, the positive data for laquinimod (MS) and perampanel and Potiga (epilepsy) will bolster physician confidence and position the drugs well in their respective markets.

Published By Datamonitor
03 May 2012
Expert View
Expert View

AAN 2012: research shows value of early disease identification, but caution in treatment is advised

At AAN 2012, Merck Serono presented data from a long-term study showing that early Rebif treatment significantly reduced the clinical progression of multiple sclerosis. However, early intervention should be used cautiously to avoid unnecessary treatment.

Published By Datamonitor
03 May 2012
ResearchWire
ResearchWire

Pack-Track Innovation of the Month: Friels Pure Apple Cider

Published By Datamonitor
08 May 2012
ResearchWire
ResearchWire

PLA Innovation of the Week: a new vodka product with a built-in aerator

Published By Datamonitor
10 May 2012

« | ... | 1015 | 1016 | 1017 | 1018 | 1019 | 1020 | 1021 | 1022 | 1023 | ... | » »|

No help is available.